

Hetlio[®] (tasimelteon)
Effective 4/1/2020

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Hetlio is an agonist of melatonin receptors which induces sleepiness and influences regulation of circadian rhythms.

Coverage Guidelines

Authorization may be granted for members who has been started and stabilized on Hetlio excluding when the product is obtained as samples or via manufacturer’s patient assistance programs

OR

Authorization may be granted for members when ALL the following criteria are met:

1. The member has a diagnosis of non-24 hour sleep-wake disorder (non-24)
1. The prescriber is a sleep specialist or is being prescribed in consult with a sleep specialist
2. The member has had at least a one-month trial of timed melatonin administration that resulted in a side effect, allergy, or treatment failure

Continuation of Therapy

Reauthorization will be granted if documentation is submitted indicating a positive response to therapy

Limitations

1. Initial approvals will be granted for 6 months
2. Reauthorizations will be granted for 12 months
3. The following quantity limits apply:

Hetlio 20mg	30 capsules per 30 days
-------------	-------------------------

References

399 Revolution Drive, Suite 810, Somerville, MA 02145 | allwayshealthpartners.org



1. Hetlioz (tasimelteon) [prescribing information]. Washington, DC: Vanda Pharmaceuticals; October 2019.
2. Lockley SW, Dressman MA, Xiao C, et al. Tasimelteon treatment entrains the circadian clock and demonstrates a clinically meaningful benefit in totally blind individuals with non-24-hour circadian rhythms. *Sleep Medicine*. 2013;14(Suppl 1): e17
3. Auger RR, Burgess HJ, Emens JS, et al. Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders: advanced sleep-wake phase disorder (ASWPD), delayed sleep-wake phase disorder (DSWPD), non-24-hour sleep-wake rhythm disorder (N24SWD), and irregular sleep-wake rhythm

Review History

09/21/2015: Reviewed P&T Mtg

12/29/2015: Implementation Date

11/27/2017: Reviewed P&T Mtg

11/26/2018: Reviewed P&T Mtg

01/22/2020: Added started and stabilized criteria, added indication of non-24 hour sleep wake disorder, removed Rozerem trial

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.